Abstract
Protein-protein interactions (PPI) play an important role in cellular signalling, the most common of which is the PDZ domain. This 90-residue domain occurs 257 times in 142 human proteins. Although these domains have well-defined binding sites which recognises short C-terminal peptide ligands (PLs), the high specificity of PDZ binding makes them an intriguing system to study. Abnormal PPI are of particular importance as they often contribute to the development of diseases. PDZ domains have been reported to be implicated in diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimers, Parkinson, avian influenza, pain, and stroke. In this review, we present the structure of PDZ domains, highlighting the high specificity of their binding to endogenous PLs, leading to their classification. We also consider their involvement in disease pathways and expand on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Keywords: PDZ domain, protein-protein interaction (PPI), PDZ inhibitor
Current Chemical Biology
Title: Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors
Volume: 3 Issue: 2
Author(s): Sylvie Ducki and Elizabeth Bennett
Affiliation:
Keywords: PDZ domain, protein-protein interaction (PPI), PDZ inhibitor
Abstract: Protein-protein interactions (PPI) play an important role in cellular signalling, the most common of which is the PDZ domain. This 90-residue domain occurs 257 times in 142 human proteins. Although these domains have well-defined binding sites which recognises short C-terminal peptide ligands (PLs), the high specificity of PDZ binding makes them an intriguing system to study. Abnormal PPI are of particular importance as they often contribute to the development of diseases. PDZ domains have been reported to be implicated in diseases such as cancer, cystic fibrosis, schizophrenia, Alzheimers, Parkinson, avian influenza, pain, and stroke. In this review, we present the structure of PDZ domains, highlighting the high specificity of their binding to endogenous PLs, leading to their classification. We also consider their involvement in disease pathways and expand on current efforts to modulate their interaction using modified peptides and small molecules as selective PDZ inhibitors.
Export Options
About this article
Cite this article as:
Ducki Sylvie and Bennett Elizabeth, Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors, Current Chemical Biology 2009; 3(2) . https://dx.doi.org/10.2174/2212796810903020146
DOI https://dx.doi.org/10.2174/2212796810903020146 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
Current Cancer Drug Targets MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Breast Cancer Diagnosis Using Data Mining Methods, Cumulative Histogram Features, and Gary Level Co-occurrence Matrix
Current Medical Imaging Promising Chemoprevention of Colonic Aberrant Crypt Foci by <i>Portunus segnis</i> Muscle and Shell Extracts in Azoxymethane-Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Drugs Targeting Parasite Lysosomes
Current Pharmaceutical Design Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry Cystic Hygroma with Multiple Benign Bone Lymphangiomas in an Adult Patient: A Rare Entity in the Differential Diagnosis of Multiple Osseous Lesions in Oncology Practice
Current Medical Imaging Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design Studies on Cancer Cell Cytotoxicity, Antimicrobial Activity of Sol-Gel Synthesized Willemite for Biomedical Applications
Current Nanoscience An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry